Skip to main content

Table 1 Demographic and clinical characteristics of HIV-1 patients receiving HAART

From: Ultrasound-assessed perirenal fat is related to increased ophthalmic artery resistance index in HIV-1 patients

Characteristic A (n = 88) B (n = 38) C (n = 50) p-value
Age (years) 42 ± 8.6 41.4 ± 7.0 44.2 ± 8.2 NS
Sex (M/F) 42/26 33/17 25/13 NS
BMI (kg/m2) 23.51 ± 2.9 24.4 ± 1.8 23.4 ± 2.2 NS
PRFT/BMI 0.2 ± 0.09 0.32 ± 0.01 0.13 ± 0.04 < 0.0001
Current smoker (%) 36.3 35.2 33.3 NS
Systolic pressure 123 ± 6.8 126.9 ± 7.3 122.0 ± 6.7 NS
HIV exposure     
Homosexual 42 (47.7%) 23 (46%) 19 (50%) NS
Heterosexual 31 (35.2%) 17 (34%) 14 (36.8) NS
IDU 15 (17%) 8 (16%) 7 (18.4%) NS
HCV coinfection (%) 20.5 20 20.8 NS
CD4 (cells/μl) 534.3 ± 251.6 533.8 ± 271.2 535 ± 212 NS
HIVRNA load (mean log10 copies) 2.06 ± 1.2 2.1 ± 1.01 1.9 ± 1.4 NS
Duration of HAART (months) 75 ± 40.9 82.4 ± 35.9 70.4 ± 43.6 NS
Total cholesterol (mg/dl) 184.5 ± 44.7 190.3 ± 54.9 180.9 ± 37 NS
HDL cholesterol (mg/dl) 51.5 ± 15 52.6 ± 16.2 50.8 ± 14.4 NS
Triglycerides (mg/dl) 156.1 ± 94.7 177.3 ± 97.8 142.7 ± 91.3 NS
Glycemia (mg/dl) 94.3 ± 11.8 92.8 ± 6.9 86.7 ± 9.2 NS
2 NRTI + 1 NNRTI 41 (46.5%) 23 (46%) 18 (47.3%) NS
2 NRTI + 1 PI 47 (53.4%) 27 (54%) 20 (52.6%) NS
  1. A, all HIV+ patients; B, HIV+ patients with visceral obesity; C, HIV+ patients without visceral obesity; BMI, body mass index; PRFT, perirenal fat thickness; IDU, intravenous drug users; HAART, highly active antiretroviral therapy; HDL, high density lipoprotein; NRTI, nucleoside reverse transcriptase; NNRTI, non-nucleoside reverse transcriptase; PI, protease inhibitor; NS, not significant. All data are expressed as mean ± standard deviation. A p-value of < 0.05 was considered to be statistically significant.